JP2016502537A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016502537A5 JP2016502537A5 JP2015545156A JP2015545156A JP2016502537A5 JP 2016502537 A5 JP2016502537 A5 JP 2016502537A5 JP 2015545156 A JP2015545156 A JP 2015545156A JP 2015545156 A JP2015545156 A JP 2015545156A JP 2016502537 A5 JP2016502537 A5 JP 2016502537A5
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- formulation
- nr2b9c
- tat
- trehalose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261730952P | 2012-11-28 | 2012-11-28 | |
| US61/730,952 | 2012-11-28 | ||
| PCT/US2013/071755 WO2014085349A1 (en) | 2012-11-28 | 2013-11-25 | Lyophilized formulation of tat-nr2b9c |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016502537A JP2016502537A (ja) | 2016-01-28 |
| JP2016502537A5 true JP2016502537A5 (enExample) | 2016-12-22 |
| JP6427104B2 JP6427104B2 (ja) | 2018-11-21 |
Family
ID=50828392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545156A Expired - Fee Related JP6427104B2 (ja) | 2012-11-28 | 2013-11-25 | Ｔａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20140162957A1 (enExample) |
| EP (1) | EP2925338B8 (enExample) |
| JP (1) | JP6427104B2 (enExample) |
| KR (1) | KR102166374B1 (enExample) |
| CN (2) | CN105101986B (enExample) |
| AU (1) | AU2013352437B2 (enExample) |
| CA (1) | CA2892965C (enExample) |
| DK (1) | DK2925338T3 (enExample) |
| ES (1) | ES2725598T3 (enExample) |
| HR (1) | HRP20190707T1 (enExample) |
| HU (1) | HUE043820T2 (enExample) |
| LT (1) | LT2925338T (enExample) |
| MX (1) | MX365325B (enExample) |
| PL (1) | PL2925338T3 (enExample) |
| PT (1) | PT2925338T (enExample) |
| SI (1) | SI2925338T1 (enExample) |
| TR (1) | TR201905787T4 (enExample) |
| WO (1) | WO2014085349A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10251935B2 (en) | 2012-11-28 | 2019-04-09 | Nono Inc. | Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose |
| US11039621B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US11039620B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US9622483B2 (en) | 2014-02-19 | 2017-04-18 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| WO2015181757A1 (en) * | 2014-05-28 | 2015-12-03 | Nono Inc. | Lyophilized formulation of tat-nr2b9c with acetylation scavenger |
| SMT202000307T1 (it) | 2014-05-28 | 2020-07-08 | Nono Inc | Sale cloruro di tat-nr2b9c |
| US20190064147A1 (en) * | 2015-01-18 | 2019-02-28 | Biogen Ma Inc. | Formulations and screening of biological therapeutic agents |
| WO2017185250A1 (zh) * | 2016-04-27 | 2017-11-02 | 拜西欧斯（北京）生物技术有限公司 | 兴奋性神经毒性相关损伤的治疗方法 |
| CN106619170A (zh) * | 2016-10-26 | 2017-05-10 | 暨南大学 | 包含stp和生长因子的活性组合物及其化妆品或护肤品 |
| CN110627877A (zh) * | 2019-09-25 | 2019-12-31 | 成都奥达生物科技有限公司 | 一种psd-95抑制剂 |
| CA3166998A1 (en) * | 2020-01-09 | 2021-07-15 | Nono Inc. | Plasmin-resistant peptides for treating stroke and related conditions |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605884A (en) * | 1987-10-29 | 1997-02-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US7510824B2 (en) * | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| US20080119412A1 (en) * | 2003-12-23 | 2008-05-22 | Nono Inc. | Polypeptides for Modulating Binding of Trp Channel Proteins and Trp- Associated Proteins |
| GB0329918D0 (en) * | 2003-12-24 | 2004-01-28 | West Pharm Serv Drug Res Ltd | Intranasal compositions |
| US7588911B2 (en) * | 2005-06-23 | 2009-09-15 | Arbor Vita Corporation | Assays for detecting inhibitors of binding between COX-2 and PDZ proteins |
| US8633160B2 (en) * | 2005-12-30 | 2014-01-21 | Nono Inc. | Small molecule inhibitors of PDZ interactions |
| BRPI0711193A2 (pt) * | 2006-05-05 | 2013-06-18 | Transtech Pharma Inc | proteÍnas de fusço rage, formulaÇÕes e mÉtodos de uso dos mesmos |
| EP1884521A1 (en) * | 2006-07-31 | 2008-02-06 | Xigen S.A. | Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins |
| US8080518B2 (en) * | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| CN102202677A (zh) * | 2008-09-03 | 2011-09-28 | 阿尔伯维塔公司 | 治疗疼痛的活性剂和方法 |
| US8099602B2 (en) * | 2008-09-26 | 2012-01-17 | Mykonos Software, Inc. | Methods for integrating security in network communications and systems thereof |
| CA2765171C (en) * | 2009-06-10 | 2018-10-02 | Nono Inc. | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| EP2440230B1 (en) * | 2009-06-10 | 2020-11-11 | NoNO Inc. | Treatment regimes for treatment of neurological disease |
| WO2012021854A2 (en) * | 2010-08-12 | 2012-02-16 | Nono, Inc. | Treatment of penetrative injury to the brain |
-
2013
- 2013-11-25 KR KR1020157017140A patent/KR102166374B1/ko not_active Expired - Fee Related
- 2013-11-25 CA CA2892965A patent/CA2892965C/en active Active
- 2013-11-25 HU HUE13859059A patent/HUE043820T2/hu unknown
- 2013-11-25 EP EP13859059.1A patent/EP2925338B8/en active Active
- 2013-11-25 AU AU2013352437A patent/AU2013352437B2/en not_active Ceased
- 2013-11-25 JP JP2015545156A patent/JP6427104B2/ja not_active Expired - Fee Related
- 2013-11-25 DK DK13859059.1T patent/DK2925338T3/da active
- 2013-11-25 SI SI201331425T patent/SI2925338T1/sl unknown
- 2013-11-25 HR HRP20190707TT patent/HRP20190707T1/hr unknown
- 2013-11-25 PL PL13859059T patent/PL2925338T3/pl unknown
- 2013-11-25 CN CN201380071653.2A patent/CN105101986B/zh not_active Expired - Fee Related
- 2013-11-25 CN CN201810971184.4A patent/CN109106941A/zh active Pending
- 2013-11-25 LT LTEP13859059.1T patent/LT2925338T/lt unknown
- 2013-11-25 PT PT13859059T patent/PT2925338T/pt unknown
- 2013-11-25 ES ES13859059T patent/ES2725598T3/es active Active
- 2013-11-25 TR TR2019/05787T patent/TR201905787T4/tr unknown
- 2013-11-25 MX MX2015006784A patent/MX365325B/es active IP Right Grant
- 2013-11-25 WO PCT/US2013/071755 patent/WO2014085349A1/en not_active Ceased
- 2013-11-26 US US14/089,752 patent/US20140162957A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016150678A (ru) | ХЛОРИДНАЯ СОЛЬ ПЕПТИДА TAT-NR2B9с, КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| JP2013079270A5 (enExample) | ||
| MX374287B (es) | Formulacion que contiene virus y uso de la misma. | |
| HRP20190707T1 (hr) | Liofilizirana formulacija tat-nr2b9c | |
| CY1117757T1 (el) | Τροποποιημενες πρωτεϊνες rsv f και μεθοδοι χρησης τους | |
| MX2019012081A (es) | Proteina de fusion del factor de crecimiento 21 de fibroblastos humanos (hfgf21), metodo de preparacion de la misma y su uso. | |
| ATE538774T1 (de) | Pharmazeutische formulierungen und verfahren zur behandlung von atemwegsinfektionen | |
| EA201270062A1 (ru) | Вакцина | |
| NZ711567A (en) | Antibody formulations | |
| EP3363458A3 (en) | A peptide | |
| BR112017015852A2 (pt) | forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1 | |
| EA201490653A1 (ru) | Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств | |
| EP4706400A3 (en) | Heat sterilized high protein compositions comprising whey protein and at least one component selected from (i) a saccharide, (ii) a phosphate and (iii) a citrate | |
| JP2015533509A5 (enExample) | ||
| MX389336B (es) | Formulacion farmaceutica. | |
| EA201991702A1 (ru) | Самосборные белковые наночастицы, инкапсулирующие иммуностимулирующие нуклеиновые кислоты | |
| BRPI0911678B8 (pt) | maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central | |
| JP2017521370A5 (enExample) | ||
| PH12015502005A1 (en) | New stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy | |
| EP2398804A4 (en) | ACID ADDITION SALT FROM UDENAFIL, METHOD OF MANUFACTURING THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH | |
| JP2016534062A5 (enExample) | ||
| WO2016019350A3 (en) | Microscale bioprocessing system and method for protein manufacturing from human blood | |
| WO2016066722A3 (en) | Bacteriophage combinations for human or animal therapy | |
| WO2011104555A3 (en) | Process for the preparation of sunitinib malate form i | |
| CY1124001T1 (el) | Υγρο αιμοκαθαρσης απαλλαγμενο απο ασβεστιο |